Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vorolanib by EyePoint Pharmaceuticals for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to...
Vorolanib by Betta Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval
Vorolanib is under clinical development by Betta Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Vorolanib by EyePoint Pharmaceuticals for Diabetic Macular Edema: Likelihood of Approval
Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Diabetic Macular Edema. According to GlobalData,...
Vorolanib by EyePoint Pharmaceuticals for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration....
Risk adjusted net present value: What is the current valuation of EyePoint Pharmaceuticals's Vorolanib?
Vorolanib is a small molecule commercialized by EyePoint Pharmaceuticals, with a leading Phase II program in Non-Proliferative Diabetic Retinopathy (NPDR)....